Marion Couch named chair of IU Head and Neck Surgery

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MARION COUCH was named the Richard T. Miyamoto Professor and chair of the Indiana University School of Medicine Department of Otolaryngology-Head and Neck Surgery. Couch will assume her duties June 1, pending approval by the trustees of Indiana University.

A head and neck surgical oncologist, she is professor and interim chair of the Department of Surgery at the University of Vermont College of Medicine and surgeon-in-chief of Fletcher Allen Health Care.

She joined the University of Vermont faculty in 2010 as division chief of otolaryngology-head and neck surgery and was appointed interim chair and physician leader of surgery in 2011. She also served as interim chief of ophthalmology and associate vice president of finance for the UVM Medical Group.

Couch will succeed Richard Miyamoto, chair and Arilla Spence DeVault Professor of Otolaryngology-Head and Neck Surgery and medical director of audiology and speech language pathology.

Miyamoto performed Indiana’s first cochlear implant in 1979. In 1995, he and his team at Riley Hospital for Children implanted a device in a 16-month-old boy, the youngest ever to receive a cochlear implant at that time.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login